Innovating Nervous System Therapies

Neuralstem (NASDAQ: CUR) is a biopharmaceutical company researching and developing novel treatments for nervous system diseases based on our neural stem cell technology.

About us
Our Lead Asset

Our Lead Asset

NSI-189 is a new chemical entity being evaluated in a Phase 2 clinical trial for major depressive disorder (MDD). NSI-189 works differently than commonly prescribed antidepressants, and may represent a new class of neurogenic drugs.

Our Pipeline

Clinical Programs

We currently have two clinical development programs: The NSI-189 small molecule program and the NSI-566 stem cell therapy program.

Our Platform

Contact Us

Do you have questions about our company, our efforts or partnerships opportunities? We’d love to hear from you.

Contact Us

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign up

Product Pipeline

Candidate & Indication Preclinical Phase 1 Phase 2 Phase 3
Small Molecule
NS-189 US Major Depressive Disorder
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NS-189 US Angelman Syndrome
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NS-189 US Cognitive Impairment
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NS-189 US Irradiation-induced cognition
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NS-189 US Diabetes-related neuropathy
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NS-189 US Ischemic Stroke
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Cell Therapy*
NSI-566 US Amyotropic Lateral Sclerosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NSI-566 US Chronic Spinal Cord Injury
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
NSI-566 China Ischemic Stroke
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

*Neuralstem corporate strategy is to seek partnerships/collaborations to fund the programs.